FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Ruiwen Zhang

Research Profile

Living Beings

Chemicals & Drugs

Procedures

Xenograft Model Antitumor Assays

Anatomy

Disorders

Neoplasms

Physiology

Concepts & Ideas

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Sharad Sharma; Xing Hu; Hang-ping Yao; Jun-Ying Zeng; Ruiwen Zhang; Yong-Qing Zhou; Chun-Mei Zhuang; Ming-Hai Wang
Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents.
Xu Zhang; Wei Zhu; Hongcui Cao; Wei Li; Hui Qian; Mei Wang; Wei Wang; Wenrong Xu; Yongmin Yan; Shengqin Ye; Leilei Zhang; Ruiwen Zhang
Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery.
Elizabeth Rayburn; Wei Wang; Hongxia Xu; Joseph Covey; Lee Jia; Moses Lee; Haibo Li; Mao Li; Jiang-Jiang Qin; Xu Zhang; Ruiwen Zhang
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Ruiwen Zhang (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Sharad Sharma; Xing Hu; Hang-ping Yao; Jun-Ying Zeng; Ruiwen Zhang; Yong-Qing Zhou; Chun-Mei Zhuang; Ming-Hai Wang
Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents.
Molecular cancer therapeutics 2013;12(5):725-36.
2013: Xu Zhang; Wei Zhu; Hongcui Cao; Wei Li; Hui Qian; Mei Wang; Wei Wang; Wenrong Xu; Yongmin Yan; Shengqin Ye; Leilei Zhang; Ruiwen Zhang
Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery.
Current cancer drug targets 2013;13(1):92-102.
2012: Elizabeth Rayburn; Wei Wang; Hongxia Xu; Joseph Covey; Lee Jia; Moses Lee; Haibo Li; Mao Li; Jiang-Jiang Qin; Xu Zhang; Ruiwen Zhang
Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.
Cancer chemotherapy and pharmacology 2012;69(6):1423-31.
2012: Wei Wang; Xuming Wu; Hongxia Xu; Lin Ao; Subhasree Ashok Nag; Elizabeth R Rayburn; Erwin G Van Meir; Hui Wang; Ming-Hai Wang; Xiangrong Zhang; Xu Zhang; Ruiwen Zhang
KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.
PloS one 2012;7(9):e44883.
2011: Juan Duan; Miao Hao; Pingting Hu; Xiaoguang Li; Ziliang Wang; Deyi Zhang; Ruiwen Zhang; Qian Ba; Hui Wang
Knockdown of ribosomal protein S7 causes developmental abnormalities via p53 dependent and independent pathways in zebrafish.
The international journal of biochemistry & cell biology 2011;43(8):1218-27.
2011: Haibo Li; Scharri J Ezell; Xiangrong Zhang; Wei Wang; Hongxia Xu; Elizabeth R Rayburn; Xu Zhang; Evrim Gurpinar; Xinyi Yang; Charnell I Sommers; Sadanandan E Velu; Ruiwen Zhang
Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.
Biomedical chromatography : BMC 2011;25(5):628-34.
2011: Xu Zhang; Wei Zhu; Hui Qian; Wenrong Xu; Ruiwen Zhang
Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer.
Journal of cellular and molecular medicine 2011;15(2):433-44.
2011: Tao Chen; Shichao Ge; He Guo; Pingting Hu; Xiaoguang Li; Yanling Liu; Dwayaja H Nadkarni; Sadanandan E Velu; Wei Wang; Yi Xu; Xinying Yang; Ruiwen Zhang; Hui Wang
Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.
PloS one 2011;6(6):e20729.
2011: Miao Hao; Wei Wang; Yuqing Zhao; Ruiwen Zhang; Hui Wang
Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors.
European journal of drug metabolism and pharmacokinetics 2011;35(3-4):109-13.
2010: Wei Wang; Elizabeth R Rayburn; Sadanandan E Velu; Deng Chen; Dwayaja H Nadkarni; Srinivasan Murugesan; Dongquan Chen; Ruiwen Zhang
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.
Breast cancer research and treatment 2010;123(2):321-31.
2010: Hongxia Xu; Zhuo Zhang; Mao Li; Ruiwen Zhang
MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change.
The Journal of biological chemistry 2010;285(24):18407-14.
2010: Feng Wang; Scharri J Ezell; Yong Zhang; Wei Wang; Elizabeth R Rayburn; Dwayaja H Nadkarni; Srinivasan Murugesan; Sadanandan E Velu; Ruiwen Zhang
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.
Investigational new drugs 2010;28(3):234-41.
2010: Scharri J Ezell; Haibo Li; Hongxia Xu; Xiangrong Zhang; Evrim Gurpinar; Xu Zhang; Elizabeth R Rayburn; Charnell I Sommers; Xinyi Yang; Sadanandan E Velu; Wei Wang; Ruiwen Zhang
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.
Marine drugs 2010;8(7):2129-41.
2009: Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Recent advances in validating MDM2 as a cancer target.
Anti-cancer agents in medicinal chemistry 2009;9(8):882-903.
2009: Wei Wang; Elizabeth R Rayburn; Jie Hang; Yuqing Zhao; Hui Wang; Ruiwen Zhang
Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD.
Lung cancer (Amsterdam, Netherlands) 2009;65(3):306-11.
2009: Tao Chen; Mian Li; Ruiwen Zhang; Hui Wang
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy.
Journal of cellular and molecular medicine 2009;13(7):1358-70.
2009: Wei Wang; Elizabeth R Rayburn; Yuqing Zhao; Hui Wang; Ruiwen Zhang
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action.
Cancer letters 2009;278(2):241-8.
2009: Wei Wang; Elizabeth R Rayburn; Sadanandan E Velu; Dwayaja H Nadkarni; Srinivasan Murugesan; Ruiwen Zhang
In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3511-8.
2009: Dwayaja H Nadkarni; Feng Wang; Wei Wang; Elizabeth R Rayburn; Scharri J Ezell; Srinivasan Murugesan; Sadanandan E Velu; Ruiwen Zhang
Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2009;5(3):227-36.
2009: Markos Leggas; Kuei-Ling Kuo; Francisco Robert; Gretchen Cloud; Mollie deShazo; Ruiwen Zhang; Mao Li; Hui Wang; Steve Davidson; John Rinehart
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Cancer chemotherapy and pharmacology 2009;63(4):731-43.
2009: Deng Chen; Jianbing Zhang; Mao Li; Elizabeth R Rayburn; Hui Wang; Ruiwen Zhang
RYBP stabilizes p53 by modulating MDM2.
EMBO reports 2009;10(2):166-72.
2008: Priya Weerasinghe; Yifei Li; Yongli Guan; Ruiwen Zhang; David Tweardy; Naijie Jing
T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling.
The Prostate 2008;68(13):1430-42.
2008: junmei hou; Disong Wang; Ruiwen Zhang; Hui Wang
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5519-30.
2008: Elizabeth R Rayburn; Ruiwen Zhang
Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?
Drug discovery today 2008;13(11-12):513-21.
2008: Wei Wang; Elizabeth R Rayburn; Miao Hao; Yuqing Zhao; Donald L Hill; Ruiwen Zhang; Hui Wang
Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.
The Prostate 2008;68(8):809-19.
2008: Zhuo Zhang; Ruiwen Zhang
Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation.
The EMBO journal 2008;27(6):852-64.
2008: Miao Hao; Yuqing Zhao; Peizhan Chen; He Huang; Hong Liu; Hualiang Jiang; Ruiwen Zhang; Hui Wang
Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes.
PloS one 2008;3(7):e2697.
2007: Lunbiao Cui; Yubang Wang; Yuan Shi; Zhengdong Zhang; Yankai Xia; Hong Sun; Shouling Wang; Jianfeng Chen; Wei Zhang; Qiang Lu; Ling Song; Qingyi Wei; Ruiwen Zhang; Xinru Wang
Overexpression of annexin a1 induced by terephthalic acid calculi in rat bladder cancer.
Proteomics 2007;7(22):4192-202.
2007: Muhammad Wasif Saif; Sandra Sellers; Mao Li; Wei Wang; Linda Cusimano; Hui Wang; Ruiwen Zhang
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2007;60(6):871-82.
2007: D Chen; Zhuo Zhang; Mao Li; Wenquan Wang; Y Li; Elizabeth R Rayburn; Donald L Hill; Hui Wang; Ruiwen Zhang
Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function.
Oncogene 2007;26(35):5029-37.
2007: Elizabeth R Rayburn; Wei Wang; Ruiwen Zhang; Hui Wang
Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53.
International journal of oncology 2007;30(6):1511-9.
2007: Hui Wang; Mao Li; Wenyao Lin; Wenquan Wang; Zhuo Zhang; Elizabeth R Rayburn; Jian Lu; Deng Chen; Xinsen Yue; Fuming Shen; Feng Jiang; Jie He; Wu Wei; Xiaofei Zeng; Ruiwen Zhang
Extracellular activity of cyclic AMP-dependent protein kinase as a biomarker for human cancer detection: distribution characteristics in a normal population and cancer patients.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(4):789-95.
2007: Hui Wang; Ying Wang; Elizabeth R Rayburn; Donald L Hill; John J Rinehart; Ruiwen Zhang
Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics.
International journal of oncology 2007;30(4):947-53.
2007: Wei Wang; Yuqing Zhao; Elizabeth R Rayburn; Donald L Hill; Hui Wang; Ruiwen Zhang
In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng.
Cancer chemotherapy and pharmacology 2007;59(5):589-601.
2007: Mao Li; Zhuo Zhang; Donald L Hill; Hui Wang; Ruiwen Zhang
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
Cancer research 2007;67(5):1988-96.
2007: Chun Fu Wu; Xiu Li Bi; Jing Yu Yang; Jia Yang Zhan; Ying Xu Dong; Jin Hui Wang; Ji Ming Wang; Ruiwen Zhang; Xian Li
Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia.
International immunopharmacology 2007;7(3):313-20.
2007: Y Zhao; Wei Wang; L Han; Elizabeth R Rayburn; Donald L Hill; Hui Wang; Ruiwen Zhang
Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 2007;3(1):51-60.
2006: Elizabeth R Rayburn; Wei Wang; Zhuo Zhang; Mao Li; Ruiwen Zhang; Hui Wang
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
The Prostate 2006;66(15):1653-63.
2006: Jing Fang; Qiao Meng; Peter K Vogt; Ruiwen Zhang; Bing-Hua Jiang
A downstream kinase of the mammalian target of rapamycin, p70S6K1, regulates human double minute 2 protein phosphorylation and stability.
Journal of cellular physiology 2006;209(2):261-5.
2006: Zhi Wang; Hui Wang; Julie K Rhie; Joseph M Covey; Ping Liang; shuyi wang; Chun Wang; Yanxue Hu; Gautam Prasad; Li Nan; Donald L Hill; Ruiwen Zhang
Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis 2006;42(2):272-6.
2006: Eric C LaCasse; Gabriele Cherton-Horvat; Kimberley E Hewitt; Lori J Jerome; Stephen J Morris; Ekambar R Kandimalla; Dong Yu; Hui Wang; Wei Wang; Ruiwen Zhang; Sudhir Agrawal; John W Gillard; Jon Durkin
Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5231-41.
2006: Hui Wang; Elizabeth R Rayburn; Wei Wang; Ekambar R Kandimalla; Sudhir Agrawal; Ruiwen Zhang
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy.
Molecular cancer therapeutics 2006;5(8):2106-14.
2006: Hui Wang; Elizabeth R Rayburn; Wei Wang; Ekambar R Kandimalla; Sudhir Agrawal; Ruiwen Zhang
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.
Molecular cancer therapeutics 2006;5(6):1585-92.
2006: Elizabeth Rose Rayburn; Hui Wang; Ruiwen Zhang
Antisense-based cancer therapeutics: are we there yet?
Expert opinion on emerging drugs 2006;11(2):337-52.
2006: Mao Li; Hui Wang; Donald L Hill; Sherman Stinson; Karen Veley; Irma Grossi; James Peggins; Joseph M Covey; Ruiwen Zhang
Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Cancer chemotherapy and pharmacology 2006;57(5):607-14.
2005: Zhuo Zhang; Hui Wang; Mao Li; Elizabeth R Rayburn; Sudhir Agrawal; Ruiwen Zhang
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway.
Oncogene 2005;24(48):7238-47.
2005: Zhuo Zhang; Hui Wang; Mao Li; Elizabeth R Rayburn; Sudhir Agrawal; Ruiwen Zhang
Novel MDM2 p53-independent functions identified through RNA silencing technologies.
Annals of the New York Academy of Sciences 2005;1058():205-14.
2005: Mao Li; Zhuo Zhang; Donald L Hill; Xinbin Chen; Hui Wang; Ruiwen Zhang
Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels.
Cancer research 2005;65(18):8200-8.
2005: Hui Wang; Mao Li; Julie K Rhie; David M Hockenbery; Joseph M Covey; Ruiwen Zhang; Donald L Hill
Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
Cancer chemotherapy and pharmacology 2005;56(3):291-8.
2005: Hui Wang; Zhi Wang; shuyi wang; Mao Li; Li Nan; Julie K Rhie; Joseph M Covey; Ruiwen Zhang; Donald L Hill
Preclinical pharmacology of epothilone D, a novel tubulin-stabilizing antitumor agent.
Cancer chemotherapy and pharmacology 2005;56(3):255-60.
2005: James A Posey; Hui Wang; Joelle Hamilton; Alma Delgrosso; Ruiwen Zhang; Timothy Freda; William C Zamboni
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Cancer chemotherapy and pharmacology 2005;56(2):182-8.
2005: Ruiwen Zhang; Hui Wang; Sudhir Agrawal
Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
Current cancer drug targets 2005;5(1):43-9.
2005: Elizabeth R Rayburn; Ruiwen Zhang; Jie He; Hui Wang
MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.
Current cancer drug targets 2005;5(1):27-41.
2005: Zhuo Zhang; Ruiwen Zhang
p53-independent activities of MDM2 and their relevance to cancer therapy.
Current cancer drug targets 2005;5(1):9-20.
2005: Zhuo Zhang; Mao Li; Elizabeth R Rayburn; Donald L Hill; Ruiwen Zhang; Hui Wang
Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(6):397-407.
2005: Elizabeth R Rayburn; Wei Wang; Ruiwen Zhang; Hui Wang
Antisense approaches in drug discovery and development.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 2005;63():227-74.
2005: Zhuo Zhang; Mao Li; Elizabeth R Rayburn; Donald L Hill; Ruiwen Zhang; Hui Wang
Oncogenes as novel targets for cancer therapy (part III): transcription factors.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(5):327-38.
2005: Hui Wang; Elizabeth R Rayburn; Ruiwen Zhang
Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.
Current pharmaceutical design 2005;11(22):2889-907.
2005: Zhuo Zhang; Mao Li; Elizabeth R Rayburn; Donald L Hill; Ruiwen Zhang; Hui Wang
Oncogenes as novel targets for cancer therapy (part II): Intermediate signaling molecules.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(4):247-57.
2005: Zhuo Zhang; Mao Li; Elizabeth R Rayburn; Donald L Hill; Ruiwen Zhang; Hui Wang
Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(3):173-90.
2004: Hue H Luu; Ruiwen Zhang; Rex C Haydon; Elizabeth Rayburn; Quan Kang; Weike Si; Jong Kyung Park; Hui Wang; Ying Peng; Wei Jiang; Tong-Chuan He
Wnt/beta-catenin signaling pathway as a novel cancer drug target.
Current cancer drug targets 2004;4(8):653-71.
2004: Gautam Prasad; Hui Wang; Donald L Hill; Ruiwen Zhang
Recent advances in experimental molecular therapeutics for malignant gliomas.
Current medicinal chemistry. Anti-cancer agents 2004;4(4):347-61.
2004: Hui Wang; Mao Li; John J Rinehart; Ruiwen Zhang
Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.
Cancer chemotherapy and pharmacology 2004;53(6):459-67.
2004: Zhuo Zhang; Hui Wang; Mao Li; Sudhir Agrawal; Xinbin Chen; Ruiwen Zhang
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53.
The Journal of biological chemistry 2004;279(16):16000-6.
2004: Hui Wang; Mao Li; John J Rinehart; Ruiwen Zhang
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1633-44.
2004: Zhuo Zhang; Hui Wang; Gautam Prasad; Mao Li; Dong Yu; James A. Bonner; Sudhir Agrawal; Ruiwen Zhang
Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1263-73.
2003: Hui Wang; Patsy Oliver; Zhuo Zhang; Sudhir Agrawal; Ruiwen Zhang
Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
Annals of the New York Academy of Sciences 2003;1002():217-35.
2003: Zhuo Zhang; Mao Li; Hui Wang; Sudhir Agrawal; Ruiwen Zhang
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(20):11636-41.
2003: Ekambar R Kandimalla; Lakshmi Bhagat; Daqing Wang; Dong Yu; Fu-Gang Zhu; Jimmy Tang; Hui Wang; Ping Huang; Ruiwen Zhang; Sudhir Agrawal
Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.
Nucleic acids research 2003;31(9):2393-400.
2003: Hui Wang; Dong Yu; Sudhir Agrawal; Ruiwen Zhang
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
The Prostate 2003;54(3):194-205.
2003: Lakshmi Bhagat; Fu-Gang Zhu; Dong Yu; Jimmy Tang; Hui Wang; Ekambar R Kandimalla; Ruiwen Zhang; Sudhir Agrawal
CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents.
Biochemical and biophysical research communications 2003;300(4):853-61.
2003: Ruiwen Zhang; Hui Wang
Antisense oligonucleotide inhibitors of MDM2 oncogene expression.
Methods in molecular medicine 2003;85():205-22.
2003: Ruiwen Zhang; Hui Wang
Antisense oligonucleotides targeting RI alpha subunit of protein kinase A. In vitro and in vivo anti-tumor activity and pharmacokinetics.
Methods in molecular medicine 2003;75():637-54.
2002: Dong Yu; Fu-Gang Zhu; Lakshmi Bhagat; Hui Wang; Ekambar R Kandimalla; Ruiwen Zhang; Sudhir Agrawal
Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties.
Biochemical and biophysical research communications 2002;297(1):83-90.
2002: Francisco Robert; Sharon A Spencer; Hoyt A Childs; Ruiwen Zhang; Ruby F Meredith; Richard H Wheeler; Martha H Hawkins; Delicia Carey
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.
Lung cancer (Amsterdam, Netherlands) 2002;37(2):189-99.
2002: Hui Wang; Jie Hang; Zhenqi Shi; Mao Li; Dong Yu; Ekambar R Kandimalla; Sudhir Agrawal; Ruiwen Zhang
Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity.
International journal of oncology 2002;21(1):73-80.
2002: Hui Wang; Patsy Oliver; Li Nan; shuyi wang; Zhi Wang; Julie K Rhie; Ruiwen Zhang; Donald L Hill
Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2'-fluoro-5-methyldeoxyuracil-beta -D-arabinofuranoside (FMAU) as tumor-imaging agents in mice.
Cancer chemotherapy and pharmacology 2002;49(5):419-24.
2002: Hui Wang; Li Nan; Dong Yu; J Russell Lindsey; Sudhir Agrawal; Ruiwen Zhang
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Molecular medicine (Cambridge, Mass.) 2002;8(4):185-99.
2002: Hui Wang; shuyi wang; Li Nan; Dong Yu; Sudhir Agrawal; Ruiwen Zhang
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
International journal of oncology 2002;20(4):745-52.
2002: Gautam Prasad; Hui Wang; Sudhir Agrawal; Ruiwen Zhang
Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
Anticancer research 2002;22(1A):107-16.
2001: Hui Wang; Gautam Prasad; J K Buolamwini; Ruiwen Zhang
Antisense anticancer oligonucleotide therapeutics.
Current cancer drug targets 2001;1(3):177-96.
2001: Hui Wang; Li Nan; Dong Yu; Sudhir Agrawal; Ruiwen Zhang
Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3613-24.
1999: Hui Wang; Q Cai; X Zeng; D Yu; S Agrawal; Ruiwen Zhang
Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(24):13989-94.
1999: Hui Wang; X Zeng; P Oliver; L P Le; Jiandong Chen; L Chen; W Zhou; Sudhir Agrawal; Ruiwen Zhang
MDM2 oncogene as a target for cancer therapy: An antisense approach.
International journal of oncology 1999;15(4):653-60.
1998: W Liu; Ruiwen Zhang
Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
International journal of oncology 1998;12(4):793-804.
1998: Z Lu; Ruiwen Zhang; J T Carpenter; Robert B Diasio
Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):325-9.
1998: Ruiwen Zhang; Y Li; Q Cai; T Liu; H Sun; Brandon D Chambless
Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I.
Cancer chemotherapy and pharmacology 1998;41(4):257-67.
1997: Q Cai; Ronald O Rahn; Ruiwen Zhang
Dietary flavonoids, quercetin, luteolin and genistein, reduce oxidative DNA damage and lipid peroxidation and quench free radicals.
Cancer letters 1997;119(1):99-107.
1997: R B Diasio; Ruiwen Zhang
Pharmacology of therapeutic oligonucleotides.
Antisense & nucleic acid drug development 1997;7(3):239-43.
1996: Ruiwen Zhang; R P Iyer; D Yu; W Tan; X Zhang; Z Lu; H Zhao; S Agrawal
Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
The Journal of pharmacology and experimental therapeutics 1996;278(2):971-9.
1996: X Zhang; Ruiwen Zhang; H Zhao; H Cai; K A Gush; Russell G Kerr; George R Pettit; Andrew Kraft
Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Cancer research 1996;56(4):802-8.
1995: Z Lu; Ruiwen Zhang; Robert B Diasio
Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy.
Clinical pharmacology and therapeutics 1995;58(5):512-22.
1995: Ruiwen Zhang; Z Lu; H Zhao; X Zhang; Robert B Diasio; I Habus; Z Jiang; R P Iyer; D Yu; S Agrawal
In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Biochemical pharmacology 1995;50(4):545-56.
1995: Ruiwen Zhang; Jieming Yan; H K Shahinian; H Shahinian; G Amin; Z Lu; T Liu; M S Saag; Z Jiang; J Temsamani; R R Martin
Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
Clinical pharmacology and therapeutics 1995;58(1):44-53.
1995: Ruiwen Zhang; Z Lu; X Zhang; H Zhao; Robert B Diasio; T Liu; Z Jiang; S Agrawal
In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
Clinical chemistry 1995;41(6 Pt 1):836-43.
1995: Ruiwen Zhang; Robert B Diasio; Z Lu; T Liu; Z Jiang; W M Galbraith; S Agrawal
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
Biochemical pharmacology 1995;49(7):929-39.
1995: Robert B Diasio; Z Lu; Ruiwen Zhang; H S Shahinian
Fluoropyrimidine catabolism.
Cancer treatment and research 1995;78():71-93.
1994: Robert B Diasio; André B P van Kuilenburg; Z Lu; Ruiwen Zhang; Henk Van Lenthe; Henk D Bakker; A H Van Gennip
Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD.
Advances in experimental medicine and biology 1994;370():7-10.
1993: Z Lu; Ruiwen Zhang; Robert B Diasio
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
Cancer research 1993;53(22):5433-8.
1993: Z H Lu; Ruiwen Zhang; Robert B Diasio
Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties.
Biochemical pharmacology 1993;46(5):945-52.
1993: Ruiwen Zhang; Z Lu; C R Diasio; T Liu; Seng-Jaw Soong
The time of administration of 3'-azido-3'-deoxythymidine (AZT) determines its host toxicity with possible relevance to AZT chemotherapy.
Antimicrobial agents and chemotherapy 1993;37(9):1771-6.
1993: Ruiwen Zhang; Z Lu; T Liu; Seng-Jaw Soong; Robert B Diasio
Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy.
Cancer research 1993;53(12):2816-22.
1993: Ruiwen Zhang; T Liu; Seng-Jaw Soong; Robert B Diasio
A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil.
Biochemical pharmacology 1993;45(10):2063-9.
1993: Ruiwen Zhang; Z Lu; T Liu; Seng-Jaw Soong; Robert B Diasio
Circadian rhythm of rat spleen cytoplasmic thymidine kinase.
Biochemical pharmacology 1993;45(5):1115-9.
1992: Z H Lu; Ruiwen Zhang; Robert B Diasio
Purification and characterization of dihydropyrimidine dehydrogenase from human liver.
The Journal of biological chemistry 1992;267(24):17102-9.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.